Authors


Hope E. Uronis, MD, MHS

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.




Kate Small, MS

Latest:

Building Efficiency and Scaling With a Remote Genetic Counseling Program

Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.


Ciara Kelly, MBBCh, BAO

Latest:

Toward Personalized Treatment Approaches in Soft Tissue Sarcomas

Ciara Kelly, MBBCh, BAO, discusses personalized treatment approaches for patients with soft tissue sarcoma.




Tarek Mekhail, MD

Latest:

Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.



Miranda Lankas

Latest:

Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.



Jeff Hosry MD

Latest:

The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.



Janellen Smith, MD

Latest:

Unmet Needs and Future Perspectives in NSCLC Treatment

The panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.



Stephanie Eisenstat, MD

Latest:

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.


Helai Hussaini, MD

Latest:

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.


Samer A. Srour, MB, ChB, MS

Latest:

Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple Myeloma

A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.


Jeffrey Wolf, MD

Latest:

Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple Myeloma

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.


Martin Chin, MD

Latest:

Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.



Wilson Gonsalves, MD

Latest:

Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.


Faiz Anwer, MD

Latest:

Cross Q&A: Role of Belantamab Mafodotin in MM

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.


Thierry Alcindor, MD, MSc

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.




John Paul Flores, MD

Latest:

Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.


J. David Prologo, MD, FSIR, ABOM-D

Latest:

How Radiologists Could Use Cryoablation to Put Cancer Pain on Ice

J. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist at Emory Healthcare, details how cryoablation can be used by radiologists to manage pain in patients with cancer.


Rukesh Yadav, MBBS

Latest:

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.